Welcome to our dedicated page for Antibe Therapeut news (Ticker: ATBPF), a resource for investors and traders seeking the latest updates and insights on Antibe Therapeut stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Antibe Therapeut's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Antibe Therapeut's position in the market.
Antibe Therapeutics Inc. (OTCQX: ATBPF) announced its participation in the Canaccord Genuity 41st Annual Growth Conference, taking place virtually from August 10-12, 2021. CEO Dan Legault and CMO Dr. Joseph Stauffer will present on August 12 at 9:00 am Eastern Time. A webcast link will be available on the company's website, with a replay accessible for 90 days after the event. Antibe is focused on developing safer therapies for inflammatory conditions using its hydrogen sulfide platform, with a pipeline that includes treatments for osteoarthritis pain and alternatives to NSAIDs.
Antibe Therapeutics Inc. (OTCQX: ATBPF) has paused its absorption, metabolism, and excretion (AME) study of otenaproxesul due to elevated liver transaminase levels in three subjects. Despite these unexpected findings, the company will continue post-administration monitoring and discuss the situation with Health Canada. Antibe maintains a robust cash position of $66 million and continues to develop other novel pain and inflammation therapies. The AME study, involving 42 subjects, is essential for determining doses for the upcoming Phase III trial.
Antibe Therapeutics (OTCQX: ATBPF) reported its fiscal 2021 results, highlighting significant advances in its lead product, otenaproxesul, which is entering Phase III trials for osteoarthritis pain. The company achieved key milestones, including FDA IND clearance and a $100 million partnership with Nuance Pharma for commercialization in China. Financially, Antibe ended the year with $72 million in cash and reported a net loss of $26.3 million. R&D expenses rose to $13.4 million driven by increased development costs. Upcoming milestones include the initiation of Phase III adaptive trials in early 2022.
Antibe Therapeutics announced a strategic collaboration with Dalriada Drug Discovery to advance drug candidates and strengthen its intellectual property. This partnership aims to leverage Dalriada's drug development expertise to enhance Antibe's pipeline, particularly for inflammatory bowel disease, which affects millions in North America. Antibe’s lead drug, otenaproxesul, is preparing for Phase III trials targeting osteoarthritis pain. Additionally, the appointment of Dr. Harvey Schipper to the Scientific Advisory Board aims to identify business opportunities within unmet medical needs.
Antibe Therapeutics Inc. (OTCQX: ATBPF) announced its participation in two virtual investor conferences in June 2021. The 2021 LD Micro Invitational XI will feature presentations by Scott Curtis and Dr. Joseph Stauffer on June 9 at 12:30 pm ET. The Raymond James Human Health Innovation Conference will showcase Dan Legault and Dr. Stauffer on June 23 at 8:40 am ET. Replays will be available for 90 days on the company's website. Antibe focuses on developing safer therapies for inflammation, including otenaproxesul, currently entering Phase III for osteoarthritis pain.
Antibe Therapeutics Inc. (OTCQX: ATBPF) announced a merger with Antibe Holdings, allowing Holdings' shareholders to receive common shares of Antibe. This strategic amalgamation eliminates a 15% royalty commitment on future licensing revenues and provides a unified intellectual property platform. Following the transaction, Antibe will issue approximately 5.87 million shares, equating to 11.4% of ownership post-deal. The merger is expected to finalize by May 31, 2021, pending shareholder approval. Financial advisors have deemed the agreement fair for all parties involved.
Antibe Therapeutics Inc. has received FDA clearance for its Investigational New Drug application for otenaproxesul, aimed at treating osteoarthritis pain. This approval allows the company to initiate human clinical trials in the U.S., with plans to begin its Phase III program later this year. The company's comprehensive submission included over 55,000 pages of data from previous Phase II trials. Antibe is focused on developing safer therapies for inflammation, with other pipeline assets targeting opioid alternatives and gastrointestinal protection.
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) announced its participation in several investor conferences in March 2021. Key events include the H.C. Wainwright Global Life Sciences Conference on March 9, Roth Capital Partners Annual Conference on March 15, and Oppenheimer & Co. 31st Annual Healthcare Conference on March 16, followed by the Maxim Group Emerging Growth Virtual Conference on March 17. Webcasts will be available on-demand on the company’s website, where replays can be accessed for 90 days.
Antibe is developing safer therapies using its hydrogen sulfide platform, targeting conditions like osteoarthritis and inflammatory bowel disease.
Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF) has reported its financial results for the quarter ending December 31, 2020. Notable achievements include preparations for Phase III trials of otenaproxesul, strategic licensing with Nuance Pharma for the Greater China region, and a rise in cash reserves to $15.4 million. Revenue increased to $2.8 million, up from $2.6 million, primarily due to Citagenix. However, the net loss widened to $6.5 million from $4.2 million, reflecting higher R&D expenses of $3.4 million. Overall, Antibe is focusing on expanding its pipeline and solidifying its market position.
Antibe Therapeutics has licensed otenaproxesul to Nuance Pharma for commercialization in Greater China, which includes China, Hong Kong, Macau, and Taiwan. The agreement grants Nuance exclusive rights and entails US$100 million in milestone payments, comprising US$20 million upfront and US$80 million based on development and sales milestones. Nuance will cover clinical and regulatory costs. The partnership aims to leverage China’s growing demand for innovative pain management therapies, particularly nonsteroidal anti-inflammatory drugs.